Hepatocellular Carcinoma in Kosovo: A Retrospective Cohort Study, 2012–2022

ORIGINAL ARTICLE
Kreshnike Dedushi, Jeton Shatri, Leotrim Berisha, Asdren Behrami, Mirlinda Berisha, Jona Kosova, Diar Kabashi

 
For citation: Dedushi K, Shatri J, Berisha L, Behrami A, Berisha M, Kosova J, Kabashi D. Hepatocellular Carcinoma in Kosovo: A Retrospective Cohort Study, 2012–2022. International Journal of Biomedicine. 2025;15(3):495-499. doi:10.21103/Article15(3)_OA5
 
Originally published September 5, 2025

Abstract: 

Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide, yet comprehensive epidemiologic data from Kosovo are lacking. We aimed to characterize trends, demographic distributions, and risk factors of HCC in Kosovo from 2012 to 2022.
Methods and Results: In this retrospective, population-based cohort study, we analyzed 103 HCC cases diagnosed at the University Clinical Center of Kosovo. Demographic and clinical data were extracted from hospital registries and supplemented with national population figures. Over the study period, 77.7% of cases were male, and the highest incidence (36.9%) occurred in patients aged 60–69 years. Major risk factors included current smoking (57.3 %) and regular alcohol consumption (20.4 %), while only 6.8% had documented hepatitis B or C (HBV/HCV) infection, suggesting underdiagnosis. A transient decline in case detection in 2020 coincided with COVID-19-related healthcare disruptions.
Conclusion: HCC incidence in Kosovo rose gradually over the past decade, with a pronounced male and older-age predominance. Strengthening viral-hepatitis screening and promoting tobacco- and alcohol-cessation programs are critical to curbing the HCC burden and improving outcomes.

Keywords: 
hepatocellular carcinoma • epidemiology • smoking • alcohol consumption
References: 
  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
  2. Petrick JL, Florio AA, Znaor A, Ruggieri D, Laversanne M, Alvarez CS, Ferlay J, Valery PC, Bray F, McGlynn KA. International trends in hepatocellular carcinoma incidence, 1978–2012. Int J Cancer. 2020 Jul 15;147(2):317–330. doi:10.1002/ijc.32723. Epub 2019 Nov 5. PMID:31597196; PMCID:PMC7470451.
  3. Valery PC, Laversanne M, Clark PJ, Petrick JL, McGlynn KA, Bray F. Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology. 2018;67:600–611.
  4. Petrick JL, Florio AA, Loomba R, McGlynn KA. Have incidence rates of liver cancer peaked in the United States? Cancer. 2020 Jul 1;126(13):3151–3155. doi:10.1002/cncr.32794. Epub 2020 Apr 15. PMID:32294255; PMCID:PMC7323860.
  5. Zhang X, El-Serag HB, Thrift AP. Sex and race disparities in the incidence of hepatocellular carcinoma in the United States examined through age–period–cohort analysis. Cancer Epidemiol Biomarkers Prev. 2020;29:88–94.
  6. Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear CT, Younossi ZM. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore). 2017 Mar;96(9):e5904. doi:10.1097/MD.0000000000005904. PMID:28248853; PMCID:PMC5340426.
  7. Duggan MA, Anderson WF, Altekruse S, Penberthy L, Sherman ME. The Surveillance, Epidemiology, and End Results (SEER) Program and pathology: toward strengthening the critical relationship. Am J Surg Pathol. 2016 Dec;40(12):e94–e102. doi:10.1097/PAS.0000000000000749. PMID:27740970; PMCID:PMC5106320.
  8. Yang JD, Mohamed EA, Aziz AO, Shousha HI, et al; Africa Network for Gastrointestinal and Liver Diseases. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol. 2017 Feb;2(2):103–111. doi:10.1016/S2468-1253(16)30161-3. Epub 2016 Dec 3. Erratum in: Lancet Gastroenterol Hepatol. 2022 Aug;7(8):704. doi:10.1016/S2468-1253(22)00208-4. PMID:28403980.
  9. Almahmudi AM, Armstrong D, Elta GH, et al. Novel developments in gastrointestinal endoscopy: role in diagnosis and management of GI motility and functional disorders. J Can Assoc Gastroenterol. 2023;7(5):331–341. doi:10.1093/jcag/gwad022.
  10. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–922. doi:10.1038/s41591-018-0104-9.
  11. Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Gastroenterology. 2023;164(4):840–856.e8. doi:10.1053/j.gastro.2022.11.034.
  12. Resuli B, Sallaku A. Hepatocellular carcinoma in Albania: incidence and risk factors. Int J Sci Res. 2016;5(1):1178–1183. doi:10.21275/NOV152992.
  13. Vuković MN, Jakšić M, Stojanović D, Smolović B. Time trends in liver cancer mortality rates in Montenegro from 1990 to 2018. Eur J Gastroenterol Hepatol. 2024 May;36(5):622–627. doi:10.1097/MEG.0000000000002736. Epub 2024 Mar 4. PMID:38477857.
  14. Singh SP, Madke T, Chand P. Global epidemiology of hepatocellular carcinoma. J Clin Exp Hepatol. 2025 Mar-Apr;15(2):102446. doi:10.1016/j.jceh.2024.102446.

Download Article
Received May 18, 2025.
Accepted July 3, 2025.
©2025 International Medical Research and Development Corporation.